Summit Therapeutics Inc. — Director's Dealing 2023

Mar 9, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Summit Therapeutics Inc. (SMMT)
CIK: 0001599298
Period of Report: 2023-03-08

Reporting Person: Zanganeh Mahkam (Director, Co-Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-03-08	Common Stock	P	15973743	$1.05	Acquired	23395269	Direct
2023-03-08	Common Stock	P	804672	$1.05	Acquired	1178529	Indirect
2023-03-08	Common Stock	P	6748629	$1.05	Acquired	9884095	Indirect

Footnotes

F1: Represents the number of shares of Common Stock that the Reporting Person purchased in the Issuer's rights offering.

F2: The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.